Olympus Management

Management criteria checks 0/4

Olympus' CEO is Stefan Kaufmann, appointed in Jan 2023, has a tenure of 1.42 years. directly owns 0.006% of the company’s shares, worth €1.10M. The average tenure of the management team and the board of directors is 1.4 years and 2.5 years respectively.

Key information

Stefan Kaufmann

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	1.4yrs
CEO ownership	0.006%
Management average tenure	1.4yrs
Board average tenure	2.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Stefan Kaufmann's remuneration changed compared to Olympus's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	JP¥27b
Dec 31 2023	n/a	n/a	JP¥39b
Sep 30 2023	n/a	n/a	JP¥57b
Jun 30 2023	n/a	n/a	JP¥126b
Mar 31 2023	n/a	n/a	JP¥138b
Dec 31 2022	n/a	n/a	JP¥138b
Sep 30 2022	n/a	n/a	JP¥127b
Jun 30 2022	n/a	n/a	JP¥122b
Mar 31 2022	JP¥661m	JP¥472m	JP¥116b
Dec 31 2021	n/a	n/a	JP¥95b
Sep 30 2021	n/a	n/a	JP¥98b
Jun 30 2021	n/a	n/a	JP¥84b
Mar 31 2021	n/a	n/a	JP¥66b
Dec 31 2020	n/a	n/a	JP¥46b
Sep 30 2020	n/a	n/a	JP¥41b
Jun 30 2020	n/a	n/a	JP¥43b
Mar 31 2020	JP¥206m	JP¥158m	JP¥52b

Compensation vs Market: Insufficient data to establish whether Stefan's total compensation is reasonable compared to companies of similar size in the German market.

Compensation vs Earnings: Stefan's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.

CEO

Stefan Kaufmann (56 yo)

1.4yrs

Tenure

JP¥661,000,000

Compensation

Mr. Stefan Kaufmann serves as Director and Representative Executive Officer of Olympus Corporation since June 2019 and 2023 respectively and had been its Executive Officer since June 2019 until 2023. Mr. K...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Yasuo Takeuchi	Representative Executive Officer	12.2yrs	JP¥382.00m	0.015% ¥ 2.6m
Andre Roggan	Executive Officer & CTO	2.2yrs	JP¥230.00m	0.0022% ¥ 365.0k
Stephen Kneebone	Corporate Officer & Chief Information Officer	2.4yrs	JP¥734.00m	no data
Stefan Kaufmann	Representative Executive Officer	1.4yrs	JP¥661.00m	0.0065% ¥ 1.1m
Tatsuya Izumi	Executive Officer & CFO	less than a year	no data	no data
Takaaki Sakurai	Vice President of Investor Relations	no data	no data	no data
Eva Gardyan-Eisenlohr	Chief Compliance Officer	less than a year	no data	no data
Neil Tanner	Global General Counsel	less than a year	no data	no data
Shigeto Ohtsuki	Executive Officer & Chief Human Resources Officer	4.4yrs	no data	0.00057% ¥ 96.3k
Tetsuo Kobayashi	Executive Officer and Chief Manufacturing & Supply Officer	no data	no data	0.0035% ¥ 598.2k
Hidenao Tsuchiya	Corporate Officer	no data	no data	no data
Minoru Okabe	Head of Urology / Gynecology Business Unit	no data	no data	no data

1.4yrs

Average Tenure

60yo

Average Age

Experienced Management: OLY's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Yasuo Takeuchi	Representative Executive Officer	12.2yrs	JP¥382.00m	0.015% ¥ 2.6m
Stefan Kaufmann	Representative Executive Officer	5yrs	JP¥661.00m	0.0065% ¥ 1.1m
Sumitaka Fujita	Independent Outside Director	12.2yrs	no data	0.0014% ¥ 228.1k
Jimmy C. Beasley	Independent Outside Director	5yrs	no data	0.00031% ¥ 52.4k
Gary John Pruden	Independent Outside Director	2yrs	no data	0.00019% ¥ 32.1k
David Robert Hale	Independent Outside Director	5yrs	no data	no data
Luann Pendy	Independent Outside Director	1.4yrs	no data	no data
Toshihiko Okubo	Director	1.4yrs	no data	0.0016% ¥ 275.5k
Sachiko Ichikawa	Independent Outside Director	3yrs	no data	0.00030% ¥ 50.7k
Kohei Kan	Independent Outside Director	2yrs	no data	0.00024% ¥ 40.6k
Koji Shingai	Independent Outside Director	2yrs	no data	no data
Kan Hengping	Independent Outside Director	2yrs	no data	no data

2.5yrs

Average Tenure

62yo

Average Age

Experienced Board: OLY's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Olympus Management

Management criteria checks 0/4

Key information

Recent management updates

Olympus Corporation, Annual General Meeting, Jun 26, 2024

Olympus Corporation Announces Executive Changes

Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer

Olympus Corporation, Annual General Meeting, Jun 27, 2023

Olympus Corporation Proposes Board Resignations

Recent updates

Olympus Corporation, Annual General Meeting, Jun 26, 2024

Olympus Corporation (TSE:7733) announces an Equity Buyback for 60,000,000 shares, representing 5.15% for ¥100,000 million.

Olympus Corporation to Report Q1, 2025 Results on Aug 07, 2024

Olympus Corporation Revises Consolidated Revenue Guidance for the Fiscal Year Ending March 31, 2024

Olympus Corporation Announces Executive Changes

Olympus Corporation (TSE:7733) completed the acquisition of Taewoong Medical Co. Ltd. from Kyong-min Shin and others.

Olympus Corporation Announces Study Results Show the S Sustained Clinical Benefits of Spiration Valve System At 24 Months

Olympus Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Olympus Corporation (TSE:7733) announces an Equity Buyback for 53,000,000 shares, representing 4.34% for ¥80,000 million.

Olympus Corporation Announces Market Launch of EVIS X1 Endoscopy System

Olympus Corporation Announces the Launch of the Vathin E-SteriScope

Olympus Corporation Announces Publication of Study Data Demonstrating That the Minimally Invasive Itind™? Treatment Provides Long-Lasting Relief of More Than Four Years

Olympus Corporation to Report Q3, 2024 Results on Feb 14, 2024

Olympus Corporation Reiterates Consolidated Financial Guidance for the Fiscal Year Ending March 2024

Olympus Names Wenlei Yang the Newly Established Chief Diversity, Equity and Inclusion Officer

Olympus Corporation, Annual General Meeting, Jun 27, 2023

Olympus Corporation Set to Demonstrate Newest Endoscopy System At DDW

Olympus Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Olympus Corporation (TSE:7733) announces an Equity Buyback for 21,000,000 shares, representing 1.65% for ¥50,000 million.

Olympus Corporation Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Olympus Launches VISERA ELITE III Surgical Visualization Platform

Bain Capital Private Equity, LP entered into a definitive agreement to acquire Scientific Solutions Business of Olympus Corporation from Olympus Corporation (TSE:7733) for approximately JPY 427.67 billion.

Olympus Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Olympus Announces the Availability of New Monitor Option, the OEV321UH Video Display Monitor

Olympus Corporation Announces Study Results Show Long-Term Efficacy of Itind Procedure

Olympus Corporation to Report Q3, 2023 Results on Feb 10, 2023

Olympus Corporation Announces Dividend for the Year Ended March 31, 2022, Payable on June 3, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Olympus Corporation to Report Fiscal Year 2022 Results on May 11, 2022

Olympus Announces FDA Clearance of the Celeris Single-Use Sinus Debrider

Olympus Corporation Proposes Board Resignations

Olympus Corporation Revises Consolidated Financial Guidance for the Fiscal Year Ending March 31, 2022

Olympus Corporation (TSE:7733) announces an Equity Buyback for 16,000,000 shares, representing 1.24% for ¥30,000 million.

Olympus Corporation Provides Earnings Guidance for the Fiscal Year Ending March 31, 2022

Accenture Japan Ltd entered into a definitive agreement to acquire Olympus Systems Corporation from Olympus Corporation (TSE:7733).

Olympus Launches Line of Airway Mobilescopes

Olympus Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022

Olympus Corporation Declares Full Year Dividend Ended March 31, 2021

Olympus Launches New Line of Five Single-Use Bronchoscopes

Olympus Corporation to Report Q3, 2022 Results on Feb 04, 2022

Olympus Corporation Announces President and CEO of Olympus to Sign an Absorption-Type Split Agreement with Olympus Medical Science Sales Corporation

Olympus Corporation Launches Comprehensive Global Educational Platform for Healthcare Professionals

Olympus Corporation to Report Q3, 2021 Results on Feb 12, 2021

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age